Study identifier:D7960C00009
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase II Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure in Participants with Atherosclerotic Cardiovascular Disease or Risk Equivalents and Elevated Low-Density Lipoprotein Cholesterol.
Atherosclerotic Cardiovascular Disease
Phase 2
No
Placebo, AZD0780
All
172
Interventional
18 Years - n/a
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Crossover Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Oct 2024 by AstraZeneca
AstraZeneca
Fortrea
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: AZD0780 Following randomization to treatment sequence, participants receive AZD0780 during period 1 or 2. | Drug: AZD0780 Dose 1 Participants will receive three bottles, each containing 35 tablets: • 1 bottle of dose a AZD0780 tablets • 1 bottle of dose b AZD0780 tablets • 1 bottle of dose c AZD0780 tablets Participants will take 1 tablet from each bottle on each scheduled day of study intervention, which will provide the AZD0780 dose. |
Placebo Comparator: Placebo Following randomization to treatment sequence, participants receive Placebo during period 1 or 2. | Drug: Placebo 0 mg (Placebo). Participants will receive bottles, with placebo tablets. Participants will take 1 tablet from each bottle on each scheduled day of study intervention, which will provide the placebo dose. |